Bermea, Kevin
Bhalodia, Aashik
Huff, Angelo
Rousseau, Sylvie
Adamo, Luigi http://orcid.org/0000-0003-2704-978X
Funding for this research was provided by:
National Institute for Health (1K08HL145108-01A1, 1K08HL145108-01A1)
NHLBI (1R01HL160716-01)
Article History
Accepted: 16 May 2022
First Online: 11 June 2022
Compliance with Ethical Standards
:
: Luigi Adamo is co-founder of i-Cordis, LLC, a start-up company focused on the development of immunomodulatory therapies for heart failure, with a special emphasis on B cells and pirfenidone derivatives. He reports a small reimbursement for 1-h consultation for Cello Health BioConsulting. He also has patents planned, issued, or pending for WO/2019/028062, WO2010121122 A3, WO2008021465 A8, and US20070249038 A1. The other authors declare that they have no conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.